NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE229222 Query DataSets for GSE229222
Status Public on May 18, 2024
Title Glutamine antagonist JHU083 reprograms immunosuppressive tumor-associated macrophages to drive tumor immunity in urologic cancers, bulk RNA-seq
Organism Mus musculus
Experiment type Expression profiling by high throughput sequencing
Summary Glutamine metabolism in the tumor microenvironment is emerging as a critical regulator of immune-mediated anti-tumor responses. We report potent tumor growth inhibition by the glutamine antagonist prodrug JHU083 in urologic tumors by JHU083-reprogrammed tumor-associated macrophages (TAMs) and tumor-infiltrating monocytes (TIMs). Using orthogonal approaches, we show that JHU083-mediated glutamine antagonism in the tumor microenvironment induces TNF, inflammatory, and mTORC1 signaling in different intra-tumoral TAM clusters. Additionally, we report that JHU083 increases proliferation in tissue-resident macrophages intratumorally and in different TAM sub-clusters. Functionally, we report that JHU083-reprogrammed TAMs have increased tumor cell phagocytosis and diminished pro-angiogenic capacities. In vivo inhibition of glutamine consumption in TAMs results in increased glycolysis, broken TCA cycle, and disruption in purine metabolism. Although the effect of glutamine antagonism was less profound on tumor-infiltrating T cells for their anti-tumor activity, it promoted a stem cell-like phenotype in CD8+ T cells and decreased the CD4+ Treg abundance. Additionally, we report that JHU083 causes a global shutdown in glutamine utilizing metabolic pathways in tumor cells, leading to reduced HIF-1, c-MYC phosphorylation, and induction of tumor cell apoptosis, all key anti-tumoral features.
 
Overall design Subcutaneous B6CaP tumors were harvested from mice treated with JHU083 or control. Tumors were dissociated and macrophages were fluorescence-activated cell sorted (FACS) by CD45+CD3-Ly6G-CD11b-F4/80+ and submitted for bulk RNA-sequencing.
 
Contributor(s) Lee AJ
Citation(s) 38701369
Submission date Apr 07, 2023
Last update date Aug 17, 2024
Contact name Alex Jea-Eun Lee
E-mail(s) alee262@jhmi.edu
Organization name Johns Hopkins University
Street address 1650 Orleans Street
City Baltimore
State/province MD
ZIP/Postal code 21231
Country USA
 
Platforms (1)
GPL24247 Illumina NovaSeq 6000 (Mus musculus)
Samples (12)
GSM7157129 Control, TAMs, mouse 951
GSM7157130 Control, TAMs, mouse 953
GSM7157131 Control, TAMs, mouse 954
This SubSeries is part of SuperSeries:
GSE230162 Glutamine antagonist JHU083 reprograms immunosuppressive tumor-associated macrophages to drive tumor immunity in urologic cancer
Relations
BioProject PRJNA953423

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE229222_JHU083_treated_vs_Control_genes_DESeq2.txt.gz 561.5 Kb (ftp)(http) TXT
GSE229222_RAW.tar 15.4 Mb (http)(custom) TAR (of RESULTS)
SRA Run SelectorHelp
Raw data are available in SRA
Processed data provided as supplementary file

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap